Unknown

Dataset Information

0

Mortality Trends for Veterans Hospitalized With Heart Failure and Pneumonia Using Claims-Based vs Clinical Risk-Adjustment Variables.


ABSTRACT: Importance:Prior studies have reported declines in mortality for patients admitted to Veterans Health Administration (VA) and non-VA hospitals using claims-based risk adjustment. These apparent mortality reductions may be influenced by changes in coding practices. Objective:To compare trends in the VA for 30-day mortality following hospitalization for heart failure (HF) and pneumonia using claims-based and clinical risk-adjustment models. Design, Setting, and Participants:This observational time-trend study analyzed admissions to a VA Medical Center with a principal diagnosis of HF, pneumonia, or sepsis/respiratory failure (RF) with a secondary diagnosis of pneumonia. Exclusion criteria included having less than 12 months of VA enrollment, being discharged alive within 24 hours, leaving against medical advice, and hospice utilization. Exposures:Admission to a VA hospital from January 2009 through September 2015. Main Outcomes and Measures:The primary outcome was 30-day, all-cause mortality. All models included age and sex. Claims-based covariates included 22 (30) comorbidities for HF (pneumonia). Clinical covariates included vital signs, laboratory values, and ejection fraction. Results:Among the 146?924 HF admissions, the mean (SD) age was 71.6 (11.4) years and 144?502 (98.4%) were men; among the 131?325 admissions for pneumonia, the mean (SD) age was 70.8 (12.3) years and 127?491 (97.1%) were men. Unadjusted 30-day mortality rates were 6.45% (HF) and 11.22% (pneumonia). Claims-based models showed an increased predicted risk of 30-day mortality over time (0.019 percentage points per quarter for HF [95% CI, 0.015 to 0.023]; 0.053 percentage points per quarter for pneumonia [95% CI, 0.043 to 0.063]). Clinical models showed declines or no change in predicted risk (-0.014 percentage points per quarter for HF [95% CI, -0.020 to -0.008]; -0.004 percentage points per quarter for pneumonia [95% CI, -0.017 to 0.008]). Claims-based risk adjustment yielded declines in 30-day mortality of 0.051 percentage points per quarter for HF (95% CI, -0.074 to -0.027) and 0.084 percentage points per quarter for pneumonia (95% CI, -0.111 to -0.056). Models adjusting for clinical covariates attenuated or eliminated these changes for HF (-0.017 percentage points per quarter; 95% CI, -0.039 to 0.006) and for pneumonia (-0.026 percentage points per quarter; 95% CI, -0.052 to 0.001). Compared with the claims-based models, the clinical models for HF and pneumonia more accurately differentiated between patients who died after 30 days and those who did not. Conclusions and Relevance:Among HF and pneumonia hospitalizations, adjusting for clinical covariates attenuated declines in mortality rates identified using claims-based models. Assessments of temporal trends in 30-day mortality using claims-based risk adjustment should be interpreted with caution.

SUBMITTER: Silva GC 

PROVIDER: S-EPMC6990854 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Mortality Trends for Veterans Hospitalized With Heart Failure and Pneumonia Using Claims-Based vs Clinical Risk-Adjustment Variables.

Silva Gabriella C GC   Jiang Lan L   Gutman Roee R   Wu Wen-Chih WC   Mor Vincent V   Fine Michael J MJ   Kressin Nancy R NR   Trivedi Amal N AN  

JAMA internal medicine 20200301 3


<h4>Importance</h4>Prior studies have reported declines in mortality for patients admitted to Veterans Health Administration (VA) and non-VA hospitals using claims-based risk adjustment. These apparent mortality reductions may be influenced by changes in coding practices.<h4>Objective</h4>To compare trends in the VA for 30-day mortality following hospitalization for heart failure (HF) and pneumonia using claims-based and clinical risk-adjustment models.<h4>Design, setting, and participants</h4>T  ...[more]

Similar Datasets

| S-EPMC8652730 | biostudies-literature
| S-EPMC5459395 | biostudies-literature
| S-EPMC8120737 | biostudies-literature
| S-EPMC4845296 | biostudies-other
| S-EPMC3991798 | biostudies-other
| S-EPMC4928632 | biostudies-literature
| S-EPMC7755001 | biostudies-literature
| S-EPMC7373913 | biostudies-literature
| S-EPMC5380482 | biostudies-literature
| S-EPMC9198133 | biostudies-literature